PET imaging in the assessment of normal and impaired cognitive function.

PET has been used to directly quantify several processes relevant to the status of cerebral health and function, including cerebral blood flow, cerebral blood volume, cerebral rate of oxygen metabolism, and cerebral glucose use. Clinically, the most commonly performed PET studies of the brain are performed with fluorine-18-fluorodeoxyglucose as the imaged radiopharmaceutical. Such scans have demonstrated diagnostic and prognostic use in evaluating patients who have cognitive impairment, and in distinguishing among primary neurodegenerative dementias and other causes of cognitive decline. In certain pathologic circumstances, the normal coupling between blood flow and metabolic needs may be disturbed, and changes in oxygen extraction fraction can have significant prognostic value.

[1]  D. Benson,et al.  Positron emission computed tomography in the diagnosis of dementia. , 1981, Transactions of the American Neurological Association.

[2]  J. Mazziotta,et al.  Positron emission tomography and autoradiography: Principles and applications for the brain and heart , 1985 .

[3]  R. Katzman.,et al.  Education and the prevalence of dementia and Alzheimer's disease , 1993, Neurology.

[4]  Roger Lecomte,et al.  Design and engineering aspects of a high resolution positron tomograph for small animal imaging , 1994 .

[5]  E. Hoffman,et al.  Tomographic measurement of local cerebral glucose metabolic rate in humans with (F‐18)2‐fluoro‐2‐deoxy‐D‐glucose: Validation of method , 1979, Annals of neurology.

[6]  E. Hoffman,et al.  Noninvasive determination of local cerebral metabolic rate of glucose in man. , 1980, The American journal of physiology.

[7]  Karl J. Friston,et al.  Regional cerebral blood flow in depression measured by positron emission tomography: the relationship with clinical dimensions , 1993, Psychological Medicine.

[8]  D Comar,et al.  Differential diagnosis of Alzheimer's disease with PET. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[9]  Magdalena Rafecas,et al.  A prototype high-resolution animal positron tomograph with avalanche photodiode arrays and LSO crystals , 2001, European Journal of Nuclear Medicine.

[10]  R. Ernst,et al.  The US economic and social costs of Alzheimer's disease revisited. , 1994, American journal of public health.

[11]  T J Spinks,et al.  Three-dimensional performance of a small-diameter positron emission tomograph. , 1997, Physics in medicine and biology.

[12]  William J Powers,et al.  The use of positron emission tomography in cerebrovascular disease. , 2003, Neuroimaging clinics of North America.

[13]  M N Cantwell,et al.  Does cerebral blood flow decline in healthy aging? A PET study with partial-volume correction. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[14]  M. Reivich,et al.  THE [14C]DEOXYGLUCOSE METHOD FOR THE MEASUREMENT OF LOCAL CEREBRAL GLUCOSE UTILIZATION: THEORY, PROCEDURE, AND NORMAL VALUES IN THE CONSCIOUS AND ANESTHETIZED ALBINO RAT 1 , 1977, Journal of neurochemistry.

[15]  D Comar,et al.  Reversal of Focal "Misery‐Perfusion Syndrome" By Extra‐Intracranial Arterial Bypass in Hemodynamic Cerebral Ischemia: A Case Study with 15O Positron Emission Tomography , 1981, Stroke.

[16]  W D Heiss,et al.  Tissue at Risk of Infarction Rescued by Early Reperfusion: A Positron Emission Tomography Study in Systemic Recombinant Tissue Plasminogen Activator Thrombolysis of Acute Stroke , 1998, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[17]  K Herholz,et al.  FDG PET and Differential Diagnosis of Dementia , 1995, Alzheimer disease and associated disorders.

[18]  G. Small,et al.  Prognostic value of regional cerebral metabolism in patients undergoing dementia evaluation: comparison to a quantifying parameter of subsequent cognitive performance and to prognostic assessment without PET. , 2003, Molecular Genetics and Metabolism.

[19]  S. Cherry,et al.  Performance evaluation of microPET: a high-resolution lutetium oxyorthosilicate PET scanner for animal imaging. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  M. Daube-Witherspoon,et al.  Performance of a brain PET camera based on anger-logic gadolinium oxyorthosilicate detectors. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[21]  A. Alavi,et al.  Positron emission tomography in aging and dementia: effect of cerebral atrophy. , 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[22]  Roger Lecomte,et al.  Initial results from the Sherbrooke avalanche photodiode positron tomograph , 1996 .

[23]  James F. Young,et al.  MicroPET: a high resolution PET scanner for imaging small animals , 1996, IEEE Nuclear Science Symposium Conference Record.

[24]  N. Foster,et al.  Alzheimer's disease , 1983, Neurology.

[25]  N. Foster,et al.  Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease , 1997, Annals of neurology.

[26]  M. Phelps,et al.  Maturational changes in cerebral function in infants determined by 18FDG positron emission tomography. , 1986, Science.

[27]  R. S. J. Frackowiak,et al.  REGIONAL CEREBRAL OXYGEN SUPPLY AND UTILIZATION IN DEMENTIAA CLINICAL AND PHYSIOLOGICAL STUDY WITH OXYGEN-15 AND POSITRON TOMOGRAPHY A CLINICAL AND PHYSIOLOGICAL STUDY WITH OXYGEN - 15 AND POSITRON TOMOHRAPHY , 1981 .

[28]  S. Sato,et al.  Developmental changes of cerebral blood flow and oxygen metabolism in children. , 1999, AJNR. American journal of neuroradiology.

[29]  William J. Powers,et al.  Importance of Hemodynamic Factors in the Prognosis of Symptomatic Carotid Occlusion , 1998 .

[30]  D. Silverman Brain 18F-FDG PET in the diagnosis of neurodegenerative dementias: comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[31]  R. Rothermel,et al.  Developmental changes in brain serotonin synthesis capacity in autistic and nonautistic children , 1999, Annals of neurology.

[32]  Richard S. J. Frackowiak,et al.  The use of positron emission tomography in the clinical assessment of dementia. , 1992, Seminars in nuclear medicine.

[33]  E. J. Hoffman,et al.  Quantitative Measurement of Local Cerebral Blood Flow in Humans by Positron Computed Tomography and 15O-Water , 1983, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[34]  P Pietrini,et al.  Association of premorbid intellectual function with cerebral metabolism in Alzheimer's disease: implications for the cognitive reserve hypothesis. , 1997, The American journal of psychiatry.

[35]  M. Albert,et al.  Apolipoprotein E epsilon4 and incidence of Alzheimer disease in a community population of older persons. , 1997, JAMA.

[36]  R A Zimmerman,et al.  The effect of focal cerebral atrophy in positron emission tomographic studies of aging and dementia. , 1990, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

[37]  K. Ishii,et al.  Cerebral glucose metabolism in patients with frontotemporal dementia. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[38]  H. Fukuyama,et al.  Significance of increased oxygen extraction fraction in five-year prognosis of major cerebral arterial occlusive diseases. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[39]  O B Paulson,et al.  Quantitation of Regional Cerebral Blood Flow Corrected for Partial Volume Effect Using O-15 Water and PET: II. Normal Values and Gray Matter Blood Flow Response to Visual Activation , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[40]  G L Brownell,et al.  Positron imaging in ischemic stroke disease using compounds labeled with oxygen 15. Initial results of clinicophysiologic correlations. , 1981, Archives of neurology.

[41]  S S Gambhir,et al.  A tabulated summary of the FDG PET literature. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[42]  J C Mazziotta,et al.  Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. , 1995, JAMA.

[43]  D. Salmon,et al.  The prevalence of dementia and Alzheimer's disease in Shanghai, China: Impact of age, gender, and education , 1990, Annals of neurology.

[44]  A. Alavi,et al.  Analysis of brain and cerebrospinal fluid volumes with MR imaging: impact on PET data correction for atrophy. Part II. Aging and Alzheimer dementia. , 1991, Radiology.

[45]  Joel S. Karp,et al.  Design evaluation of A-PET: A high sensitivity animal PET camera , 2003 .

[46]  J. Hoffman,et al.  FDG PET imaging in patients with pathologically verified dementia. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[47]  A. Alavi,et al.  The [18F]Fluorodeoxyglucose Method for the Measurement of Local Cerebral Glucose Utilization in Mane , 1979, Circulation research.

[48]  G. Waldemar,et al.  Heterogeneous cerebral glucose metabolism in normal pressure hydrocephalus. , 1995, Journal of neurology, neurosurgery, and psychiatry.

[49]  K. Ishii,et al.  Evaluation of standardized uptake value to assess cerebral glucose metabolism. , 2000, Clinical nuclear medicine.

[50]  T Jones,et al.  Regional cerebral oxygen supply and utilization in dementia. A clinical and physiological study with oxygen-15 and positron tomography. , 1981, Brain : a journal of neurology.

[51]  S. Thibodeau,et al.  Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. , 1996, The New England journal of medicine.

[52]  G. Alexander,et al.  Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. , 2001, JAMA.

[53]  A. Alavi,et al.  Analysis of brain and cerebrospinal fluid volumes with MR imaging. Part I. Methods, reliability, and validation. , 1991, Radiology.

[54]  Bruce G. Link,et al.  Relationship between lifetime occupation and parietal flow , 1995, Neurology.

[55]  G. Alexander,et al.  Inverse relationship between education and parietotemporal perfusion deficit in Alzheimer's disease , 1992, Annals of neurology.

[56]  Jeffrey L. Cummings,et al.  Practice parameter: Diagnosis of dementia (an evidence-based review) Report of the Quality Standards Subcommittee of the American Academy of Neurology , 2001 .

[57]  D. Evans,et al.  Estimated prevalence of Alzheimer's disease in the United States. , 1990, The Milbank quarterly.

[58]  A. Alavi,et al.  18F-2-deoxy-2-fluoro-D-glucose as a tracer in the positron emission tomographic study of senile dementia. , 1982, The American journal of psychiatry.

[59]  G. Alexander,et al.  The neurometabolic landscape of cognitive decline: in vivo studies with positron emission tomography in Alzheimer's disease. , 2000, International journal of psychophysiology : official journal of the International Organization of Psychophysiology.

[60]  J. Mazziotta,et al.  Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[61]  Michael E. Phelps,et al.  Effects of stroke on local cerebral metabolism and perfusion: Mapping by emission computed tomography of 18FDG and 13NH3 , 1980, Annals of neurology.

[62]  J. Mazziotta,et al.  Positron emission tomography study of human brain functional development , 1987, Annals of neurology.

[63]  H. Chugani A critical period of brain development: studies of cerebral glucose utilization with PET. , 1998, Preventive medicine.

[64]  Michael D. Devous,et al.  Functional brain imaging in the dementias: role in early detection, differential diagnosis, and longitudinal studies , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[65]  G Marchal,et al.  Voxel-based mapping of irreversible ischaemic damage with PET in acute stroke. , 1999, Brain : a journal of neurology.

[66]  F. Fazio,et al.  Impairment of Neocortical Metabolism Predicts Progression in Alzheimer’s Disease , 1999, Dementia and Geriatric Cognitive Disorders.

[67]  J. Mazziotta,et al.  Tomographic mapping of human cerebral metabolism , 1981, Neurology.

[68]  J. Morris,et al.  Current concepts in the pathogenesis of Alzheimer's disease. , 1997, The American journal of medicine.

[69]  Michael E. Phelps,et al.  Clinical Value of Neuroimaging in the Diagnosis of Dementia. Sensitivity and Specificity of Regional Cerebral Metabolic and Other Parameters for Early Identification of Alzheimer's Disease. , 1999, Clinical positron imaging : official journal of the Institute for Clinical P.E.T.

[70]  G. Alexander,et al.  The Metabolic Topography of Normal Aging , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[71]  N C Andreasen,et al.  Age-related changes in regional cerebral blood flow among young to mid-life adults. , 1999, Neuroreport.